Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Protometrix Inc.

This article was originally published in Start Up

Executive Summary

Protometrix's microarray technology enables it to produce, purify, and assay thousands of proteins at once on a solid surface. With this skill set, the company believes it can become the first firm able to offer drug developers the ability to scan the entire human proteome in a high-throughput setting.

You may also be interested in...



Genotyping and the High-Throughput Legacy

A deluge of DNA sequence and gene expression data generated in the last five years encouraged the original high-throughput mentality within genomics companies. Mapping the human genome provided the impetus for developing technologies for high-throughput DNA sequencing and analysis. Now genotyping, or the detection and analysis of individual genetic variations, has become the newest market around which companies are preaching the need for high-throughput methodologies.While only a handful of companies were directly involved in assisting the Human Genome Project, genotyping--the detection and analysis of individual genetic variations--has been fueling technology development, with applications in basic research through drug development. But in genotyping, high throughput is the goal but is not yet the reality. On the other hand, even if it's early to be talking about the successful integration of genotyping technologies and data, current players are already pushing their technologies onto their customers' platforms. If a company isn't already a player, it may be too late.

Pharma’s Digital Pathology Build-Out; Part 2 – What It Means

Both providers and users of digital pathology are confident that clinical use cases and the evidence needed to assure payers and encourage investment by commercial labs will overcome challenges around access and adoption.

Pharma’s Digital Pathology Build-Out; Part 1 – The State Of Play

Pharma companies are applying digital pathology throughout their research and development functions. Where are they now finding value?

Topics

Related Companies

Related Deals

Latest Headlines
See All
UsernamePublicRestriction

Register

SC090630

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel